First Patient Dosed in Phase 2 ACTIVATE Trial of BIA 28-6156 for ...

BIAL R&D initiated a phase 2 trial, ACTIVATE, for BIA 28-6156, targeting GBA1-mutated Parkinson's disease. The trial aims to assess efficacy, safety, and tolerability in 237 patients across North America and Europe, with results expected by 2026. BIA 28-6156 activates GCase, potentially delaying disease progression.